Crossmark Global Holdings Inc. Buys 436 Shares of Repligen Co. (NASDAQ:RGEN)

Crossmark Global Holdings Inc. grew its stake in Repligen Co. (NASDAQ:RGEN) by 12.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,068 shares of the biotechnology company’s stock after purchasing an additional 436 shares during the period. Crossmark Global Holdings Inc.’s holdings in Repligen were worth $606,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of RGEN. Andra AP fonden purchased a new position in Repligen during the second quarter worth $25,000. International Assets Investment Management LLC purchased a new position in shares of Repligen during the 2nd quarter worth about $33,000. UMB Bank n.a. grew its holdings in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the last quarter. Lazard Asset Management LLC raised its position in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. Finally, Blue Trust Inc. lifted its stake in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $124.73 on Friday. The company has a market cap of $6.99 billion, a PE ratio of -337.10, a P/E/G ratio of 4.36 and a beta of 0.96. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The firm’s 50 day moving average price is $141.54 and its 200-day moving average price is $144.77.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the company posted $0.23 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. Sell-side analysts forecast that Repligen Co. will post 1.44 EPS for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the topic of a number of analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. UBS Group decreased their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.